Agios Pharmaceuticals (AGIO) Competitors $29.60 -0.52 (-1.71%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGIO vs. BPMC, ELAN, LEGN, TGTX, TLX, VRNA, LNTH, AXSM, GRFS, and NUVLShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), Grifols (GRFS), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Blueprint Medicines Elanco Animal Health Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus Axsome Therapeutics Grifols Nuvalent Blueprint Medicines (NASDAQ:BPMC) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Which has better earnings and valuation, BPMC or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M11.60-$67.09M-$2.47-40.88Agios Pharmaceuticals$37.04M46.79$673.72M$11.242.66 Does the MarketBeat Community believe in BPMC or AGIO? Blueprint Medicines received 62 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 68.23% of users gave Blueprint Medicines an outperform vote while only 66.76% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes55468.23% Underperform Votes25831.77% Agios PharmaceuticalsOutperform Votes49266.76% Underperform Votes24533.24% Does the media favor BPMC or AGIO? In the previous week, Blueprint Medicines had 8 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Blueprint Medicines and 7 mentions for Agios Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.51 beat Agios Pharmaceuticals' score of 1.41 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Agios Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BPMC or AGIO? Blueprint Medicines currently has a consensus target price of $126.56, indicating a potential upside of 25.34%. Agios Pharmaceuticals has a consensus target price of $56.00, indicating a potential upside of 87.16%. Given Agios Pharmaceuticals' higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has more volatility & risk, BPMC or AGIO? Blueprint Medicines has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Is BPMC or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,845.92% compared to Blueprint Medicines' net margin of -13.19%. Agios Pharmaceuticals' return on equity of -2.51% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-13.19% -77.49% -20.84% Agios Pharmaceuticals 1,845.92%-2.51%-2.26% SummaryBlueprint Medicines beats Agios Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$6.47B$5.32B$8.43BDividend YieldN/A2.64%5.21%4.10%P/E Ratio2.649.0626.7719.71Price / Sales46.79254.27390.22118.35Price / CashN/A65.8538.2534.62Price / Book1.116.416.754.50Net Income$673.72M$143.98M$3.23B$248.32M7 Day Performance5.88%1.97%1.55%-0.09%1 Month Performance6.86%4.09%12.22%12.89%1 Year Performance-10.52%-2.83%16.71%7.33% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals3.9894 of 5 stars$29.60-1.7%$56.00+89.2%-11.1%$1.71B$37.04M2.61390Positive NewsAnalyst DowngradeBPMCBlueprint Medicines2.6438 of 5 stars$100.31+3.2%$126.56+26.2%-2.0%$6.48B$562.12M-92.88640Positive NewsInsider TradeELANElanco Animal Health3.5038 of 5 stars$12.82+7.2%$15.00+17.0%-24.4%$6.36B$4.43B32.049,800Positive NewsAnalyst ForecastLEGNLegend Biotech3.5317 of 5 stars$32.38+1.9%$78.82+143.4%-34.1%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionGap UpTGTXTG Therapeutics3.8231 of 5 stars$34.99+4.0%$40.80+16.6%+106.0%$5.56B$386.39M-349.87290Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/APositive NewsVRNAVerona Pharma1.8244 of 5 stars$67.53+6.6%$81.50+20.7%+492.7%$5.48B$118.54M-35.1730Positive NewsGap DownLNTHLantheus4.4513 of 5 stars$79.52-2.7%$132.67+66.8%-6.9%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeAXSMAxsome Therapeutics4.7176 of 5 stars$110.16+2.2%$172.14+56.3%+35.4%$5.42B$432.16M-18.39380Positive NewsAnalyst ForecastInsider TradeGRFSGrifols3.0009 of 5 stars$7.73+8.9%N/A+6.8%$5.31B$7.21B6.6126,300NUVLNuvalent2.478 of 5 stars$73.63+5.4%$115.50+56.9%+5.6%$5.27BN/A-21.2240News CoveragePositive News Related Companies and Tools Related Companies Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Verona Pharma Alternatives Lantheus Alternatives Axsome Therapeutics Alternatives Grifols Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGIO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AGIO Stock Free AGIO Stock Alerts